Geode Capital Management LLC Has $35.80 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Geode Capital Management LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,431,911 shares of the company's stock after buying an additional 656,003 shares during the period. Geode Capital Management LLC owned about 1.93% of Recursion Pharmaceuticals worth $35,803,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in RXRX. Barclays PLC raised its position in Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company's stock valued at $4,596,000 after acquiring an additional 244,278 shares in the last quarter. Wellington Management Group LLP bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $692,000. State Street Corp lifted its holdings in shares of Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Stifel Financial Corp boosted its holdings in Recursion Pharmaceuticals by 48.8% in the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company's stock valued at $1,067,000 after purchasing an additional 53,103 shares during the period. Finally, Benjamin Edwards Inc. raised its position in shares of Recursion Pharmaceuticals by 13,196.3% during the third quarter. Benjamin Edwards Inc. now owns 162,481 shares of the company's stock valued at $1,071,000 after buying an additional 161,259 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Analyst Ratings Changes

A number of research firms have weighed in on RXRX. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Jefferies Financial Group dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $9.25.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded up $0.42 on Thursday, reaching $7.66. The company's stock had a trading volume of 17,414,268 shares, compared to its average volume of 6,861,454. The business's fifty day moving average price is $6.80 and its 200 day moving average price is $7.16. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -5.01 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the company earned ($0.43) EPS. The firm's quarterly revenue was up 147.6% on a year-over-year basis. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,697,960.96. The trade was a 2.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 101,788 shares of company stock worth $682,691 over the last 90 days. 15.75% of the stock is owned by insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.